Please select the eligibility criteria that correspond to the clinical trial below.
Title: Low Energy Density Diet and Weight Loss Maintenance
Brief Summary: Investigators presumed that low energy density (LED) diet consumers will have lower risk of cardiovascular disease and are able to maintain their weight longer .


Options:
A: Inclusion Criteria:

* who were on weight loss diet for the last one year and additionally, they did not want to lose more weight.
* Non-pregnant, non-lactaries and non-smokers aged 40-70 years included in the present study

Exclusion Criteria:

* dietary poor compliance
B: Inclusion Criteria:

* Body mass index in the range of 22.0 - 27.0 kg/m2,
* Fasting blood glucose \<110mg/dL (without medication)
* LDL-cholesterol \<180 mg/dL (without medication)
* Blood pressure \<140/90 mmHg (without medication)
* Stable weight (change \<± 10%) for 3 months immediately prior to the study,
* No history of metabolic disorders or cardiovascular disease
* No acute or chronic inflammatory disorder
* No current medications to regulate blood sugar, blood pressure or lipids or hormones
* No heavy drinking (more than 15 drinks/week)
* No use of tobacco or recreational drugs within past 5 years
* No dietary restrictions (e.g. vegetarianism and vegan)

Exclusion Criteria:

* Known Malignancy
* Women who are pregnant, breast-feeding or trying to become pregnant
* History of any chronic disease process that could interfere with interpretation of study results
* Women or men on hormonal supplementation or anti-conceptive hormonal medication for at least 2 months
* Therapy with antidepressants within past 6 months
* Regular therapy with acetylsalicylic acid
C: Inclusion Criteria:

1. The volunteer (male or non-pregnant female, any ethnicity) must be \>18 years of age.
2. The volunteer must either have a body mass index of 25.0-35.0 kg/m2 or the combination of a body mass index of 18.5-24.9 kg/m2 and two or more previously or currently measured symptoms of the metabolic syndrome (fasting glucose≥110 mg/dL, triglycerides≥150 mg/dL, high-density lipoprotein cholesterol\<40 mg/dL in males or \<50 mg/dL in females, systolic blood pressure≥130 mmHg or diastolic blood pressure≥85 mmHg, or waist circumference≥40 inches in males or ≥36 inches in females \[glucose and cholesterol levels may be self-reported\]).
3. The volunteer has not routinely participated in caloric restriction (deliberate limitation of caloric intake of \<80% than the FDA-recommended daily caloric intake) within the last 2 years, has not participated in extended fasting (\>12 hours at a time) for at least a year, and does not deliberately skip meals as a routine dietary practice.

Exclusion Criteria:

1. Body mass index \<18.5 or \>35 kg/m2.
2. Current active cancer treatment, treatment with immunosuppressive medications, or solid organ transplantation within 1 year.
3. Presence of immunosuppressive disease, myocardial infarction, peripheral vascular disease, or stroke within the past year.
4. Use of insulin.
5. Although it is unlikely fasting will harm the pregnant or lactating woman, the dietary restrictions placed on the participant for the duration of the study may conflict with dietary recommendations for pregnant or lactating women. Women of child bearing potential, therefore, will meet an exclusion if they become pregnant.
D: Inclusion Criteria:

* Women and men aged 35 to 65 years
* Overweight or obese (BMI ≥ 25 kg/m2 ≤ 40 kg/m2 )
* German speaking
* Non- smoker
* Provision of written informed consent

Exclusion Criteria:

* Not able to understand and sign the informed consent form in person
* Already diagnosed diabetes
* HbA1c ≥ 6.5 % and/or fasting plasma glucose \> 125 mg/dl
* History of cancer within the past 10 years
* Risk of bleeding disorders (e.g. Marcumar intake)
* Current or history of eating disorders (bulimia, anorexia, binge-eating)
* Pregnant or lactating during the past 12 months
* Increased or decreased thyroid-stimulating hormone in baseline blood check
* Already diagnosed hepatic dysfunction and/or increased or decreased γ-GT, GPT and/or GOT in baseline blood check
* Already diagnosed kidney dysfunction and/or increased or decreased creatinine, urea and/or uric acid in baseline blood check
* Medications that might affect the endpoints of the study e.g. immunosuppressive medication (cortisol, antibody treatment), hormone replacement therapy, medication for fat metabolism (e.g. statine, fibrate)
* Participation in another intervention study shorter than three months ago

Answer: A